RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Segment A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to determine Harmless dosing routine. Supplemental members is going to be enrolled for the recognized monotherapy dosign program. In Section B, participants will receive oral ruxolitinib and ABBV-744 are going to be presented as "include-on" therapy. In